Net Income (Loss) Attributable to Parent in USD of Tenaya Therapeutics, Inc. from Q1 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Tenaya Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q1 2020 to Q3 2025.
  • Tenaya Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$20.3M, a 20.9% increase year-over-year.
  • Tenaya Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$94.3M, a 19.6% increase year-over-year.
  • Tenaya Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$111M, a 10.4% increase from 2023.
  • Tenaya Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$124M, a 0.34% decline from 2022.
  • Tenaya Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$124M, a 70.1% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Tenaya Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$94.3M -$20.3M +$5.36M +20.9% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025
Q2 2025 -$99.6M -$23.3M +$6.15M +20.9% 01 Apr 2025 30 Jun 2025 10-Q 10 Nov 2025
Q1 2025 -$106M -$26.9M +$5.36M +16.6% 01 Jan 2025 31 Mar 2025 10-Q 10 Nov 2025
Q4 2024 -$111M -$23.8M +$6.1M +20.4% 01 Oct 2024 31 Dec 2024 10-K 10 Mar 2025
Q3 2024 -$117M -$25.6M +$3.51M +12% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025
Q2 2024 -$121M -$29.4M +$3.84M +11.5% 01 Apr 2024 30 Jun 2024 10-Q 10 Nov 2025
Q1 2024 -$125M -$32.2M -$491K -1.55% 01 Jan 2024 31 Mar 2024 10-Q 10 Nov 2025
Q4 2023 -$124M -$29.9M +$3.58M +10.7% 01 Oct 2023 31 Dec 2023 10-K 10 Mar 2025
Q3 2023 -$128M -$29.1M +$1.55M +5.06% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024
Q2 2023 -$129M -$33.3M -$4.87M -17.2% 01 Apr 2023 30 Jun 2023 10-Q 06 Nov 2024
Q1 2023 -$124M -$31.7M -$681K -2.19% 01 Jan 2023 31 Mar 2023 10-Q 06 Nov 2024
Q4 2022 -$124M -$33.5M -$7.37M -28.2% 01 Oct 2022 31 Dec 2022 10-K 18 Mar 2024
Q3 2022 -$116M -$30.7M -$12.4M -68.1% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023
Q2 2022 -$104M -$28.4M -$13.2M -86.7% 01 Apr 2022 30 Jun 2022 10-Q 08 Nov 2023
Q1 2022 -$90.7M -$31.1M -$18M -137% 01 Jan 2022 31 Mar 2022 10-Q 08 Nov 2023
Q4 2021 -$72.7M -$26.2M -$15.8M -153% 01 Oct 2021 31 Dec 2021 10-K 08 Mar 2023
Q3 2021 -$56.9M -$18.3M -$7.97M -77.4% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 -$48.9M -$15.2M -$6.48M -74.2% 01 Apr 2021 30 Jun 2021 10-Q 10 Nov 2022
Q1 2021 -$42.4M -$13.1M -$4.05M -44.7% 01 Jan 2021 31 Mar 2021 10-Q 10 Nov 2022
Q4 2020 -$38.4M -$10.3M 01 Oct 2020 31 Dec 2020 10-K 23 Mar 2022
Q3 2020 -$10.3M 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021
Q2 2020 -$8.73M 01 Apr 2020 30 Jun 2020 10-Q 10 Nov 2021
Q1 2020 -$9.05M 01 Jan 2020 31 Mar 2020 10-Q 10 Nov 2021

Tenaya Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$111M +$13M +10.4% 01 Jan 2024 31 Dec 2024 10-K 10 Mar 2025
2023 -$124M -$419K -0.34% 01 Jan 2023 31 Dec 2023 10-K 10 Mar 2025
2022 -$124M -$50.9M -70.1% 01 Jan 2022 31 Dec 2022 10-K 18 Mar 2024
2021 -$72.7M -$34.3M -89.4% 01 Jan 2021 31 Dec 2021 10-K 08 Mar 2023
2020 -$38.4M 01 Jan 2020 31 Dec 2020 10-K 23 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.